Inhibikase Therapeutics, Inc.
IKT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $38,270 | $77,743 | $73,441 | $56,491 |
| Short-Term Investments | $39,053 | $9,923 | $19,739 | $41,053 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $1,214 | $1,129 | $984 | $908 |
| Total Curr. Assets | $78,537 | $88,795 | $94,165 | $98,451 |
| Property Plant & Equip (Net) | $0 | $59 | $117 | $149 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1,058 | -$0 | -$0 | $0 |
| Total NC Assets | $1,058 | $59 | $117 | $149 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $79,595 | $88,853 | $94,281 | $98,600 |
| Liabilities | – | – | – | – |
| Payables | $621 | $2,704 | $1,692 | $943 |
| Short-Term Debt | $0 | $38 | $75 | $111 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $6,076 | $6,058 | $6,784 | $2,680 |
| Total Curr. Liab. | $6,696 | $8,800 | $8,551 | $3,734 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | -$0 | $0 | $0 |
| Total NC Liab. | $0 | -$0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $38 | $75 | $111 |
| Total Liabilities | $6,696 | $8,800 | $8,551 | $3,734 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $75 | $75 | $74 | $69 |
| Retained Earnings | -$129,945 | -$118,014 | -$108,099 | -$94,421 |
| AOCI | -$4 | -$3 | -$1 | -$37 |
| Other Equity | $202,773 | $197,996 | $193,756 | $189,255 |
| Total Equity | $72,898 | $80,054 | $85,731 | $94,866 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $79,595 | $88,853 | $94,281 | $98,600 |
| Net Debt | -$38,270 | -$77,705 | -$73,367 | -$56,380 |